Oric Pharmaceuticals, Inc.
ORIC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ORIC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ORIC
Oric Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting cancer resistance mechanisms, with lead programs rinzimetostat and enozertinib.
Key risk: No revenue and operating losses
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.37B
Cash Runway
24.3 moLead Asset
enozertinib (Phase 1)
Next Catalyst
Phase3_Topline · Sep 1, 2030Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 4 clinical trials · 1 catalyst for Oric Pharmaceuticals, Inc..
Oric Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting cancer resistance mechanisms, with lead programs rinzimetostat and enozertinib.
- Lead clinical programs are rinzimetostat (ORIC-944) and enozertinib, targeting cancer resistance mechanisms [sec_mda · as of 2026-08-03].
- Cash and equivalents of $38.0M as of 2026-06-30 [sec].
- Net loss of $41.5M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $324.0M as of 2026-06-30 [sec].
- Accumulated deficit of $728.0M as of March 31, 2026 [sec_mda · as of 2026-05-04].
What works
- Strategic pipeline prioritization in August 2025 focused resources on two lead clinical programs, rinzimetostat and enozertinib, eliminating discovery research to conserve capital [sec_mda · as of 2026-08-03].
- Raised $125.0M in gross proceeds from a private placement in May 2025, providing additional funding for development [sec_mda · as of 2026-08-03].
- Phase 3 trial for rinzimetostat in combination with darolutamide is planned with topline data expected by 2030-09-01 [upcoming catalysts].
What to weigh
- No revenue generated to date; the company does not expect meaningful revenue unless regulatory approval and commercialization occur [sec_mda · as of 2026-08-03].
- Net loss of $77.3M for the six months ended June 30, 2026, and accumulated deficit of $728.0M as of March 31, 2026 [sec_mda · as of 2026-08-03].
- Cash and equivalents of $38.0M as of 2026-06-30 may be insufficient to fund operations without additional capital [sec].
- Risks include potential delays, unforeseen expenses, and reliance on successful clinical trials and regulatory approvals [sec_mda · as of 2026-08-03].
From the filings
Quoted directly from source documents.
Strategic pipeline prioritization focused on rinzimetostat and enozertinib.
“On August 12, 2025, we announced a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of our two lead clinical programs, rinzimetostat and enozertinib.”
SEC MD&A · August 3, 2026
No revenue generated to date.
“To date, we have not generated any revenue.”
SEC MD&A · August 3, 2026
Net loss for six months ended June 30, 2026 was $77.3 million.
“Our net loss for the six months ended June 30, 2026, was $77.3 million”
SEC MD&A · August 3, 2026
Accumulated deficit of $728.0 million as of March 31, 2026.
“accumulated deficit of $728.0 million as of March 31, 2026”
SEC MD&A · May 4, 2026
Catalyst timeline
- 2030-09-01 · Phase 3 topline data for rinzimetostat (ORIC-944) in combination with darolutamide — Topline results from a Phase 3 randomized, open-label study of rinzimetostat plus darolutamide will be a key efficacy readout.
Risks & what to watch (4)›
Key risks
- No revenue and operating losses — No revenue generated to date; net loss of $77.3M for six months ended June 30, 2026 [sec_mda · as of 2026-08-03].
- Cash runway uncertainty — Cash of $38.0M as of 2026-06-30 may be insufficient; company may need additional capital [sec].
- Clinical and regulatory risks — Product candidates are in clinical development; subject to delays, failures, and regulatory hurdles [sec_mda · as of 2026-08-03].
- Dependence on lead programs — Pipeline narrowed to two candidates; failure of either could significantly impact the company [sec_mda · as of 2026-08-03].
What to watch
- Phase 3 topline data for rinzimetostat in combination with darolutamide expected by 2030-09-01 [upcoming catalysts].
- Enrollment and interim data updates for enozertinib in first-line NSCLC trials [sec_mda · as of 2025-11-13].
- Cash position and any additional financing activities given $38.0M cash as of 2026-06-30 [sec].
- Regulatory updates for rinzimetostat and enozertinib [sec_mda · as of 2026-08-03].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Oric Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Oric Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
24.3 months
D/E 0.06 · 0% dilution
Lead: Phase 3
5 candidates
1 upcoming, next in ~1463d
0 buys · 3 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
176
Total value held
$1.12B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 7,374,014 | $93.4M |
| blackrock, inc. | 5,984,552 | $75.8M |
| viking global investors lp | 5,824,533 | $73.8M |
| alkeon capital management llc | 4,504,096 | $57.1M |
| state street corp | 3,702,196 | $46.9M |
| vivo capital, llc | 3,697,572 | $46.8M |
| column group llc | 3,540,777 | $44.9M |
| siren, l.l.c. | 2,998,192 | $38.0M |
| orbimed advisors llc | 2,693,929 | $34.1M |
| woodline partners lp | 2,495,030 | $31.6M |
Showing top 10 of 176 institutional holders of Oric Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 21.5%
- Days to cover
- 9.2
- Shares short
- 22,009,149
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ORIC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Oric Pharmaceuticals, Inc.?
Oric Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting cancer resistance mechanisms, with lead programs rinzimetostat and enozertinib.
What is Oric Pharmaceuticals, Inc.'s lead drug candidate?
Oric Pharmaceuticals, Inc.'s most advanced tracked candidate is enozertinib (Phase 1) for Non-small cell lung cancer (NSCLC) with EGFR exon 20 and EGFR atypical mutations.
What is Oric Pharmaceuticals, Inc.'s next catalyst?
Oric Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide" — expected September 1, 2030.
Who is the CEO of Oric Pharmaceuticals, Inc.?
Dr. Jacob M. Chacko M.B.A., M.D. is the chief executive officer of Oric Pharmaceuticals, Inc. (ORIC).
Where is Oric Pharmaceuticals, Inc. headquartered?
Oric Pharmaceuticals, Inc. (ORIC) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.